Brokerages predict that Catalyst Pharmaceuticals (NASDAQ:CPRX) will report earnings of ($0.06) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Catalyst Pharmaceuticals’ earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.07). Catalyst Pharmaceuticals also reported earnings of ($0.06) per share during the same quarter last year. The business is scheduled to issue its next earnings report on Wednesday, May 9th.
According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full-year earnings of ($0.36) per share for the current fiscal year, with EPS estimates ranging from ($0.58) to ($0.23). For the next year, analysts expect that the firm will post earnings of ($0.11) per share, with EPS estimates ranging from ($0.23) to ($0.01). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06).
Several research analysts recently issued reports on CPRX shares. BidaskClub cut shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 24th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, December 21st. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $6.25.
Shares of Catalyst Pharmaceuticals stock opened at $2.37 on Thursday. Catalyst Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $4.51.
In other news, insider Patrick J. Mcenany purchased 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 3rd. The shares were bought at an average price of $2.29 per share, for a total transaction of $45,800.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 9.60% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC grew its position in Catalyst Pharmaceuticals by 132.2% during the fourth quarter. Two Sigma Securities LLC now owns 26,658 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 15,178 shares during the period. Tanaka Capital Management Inc. grew its position in Catalyst Pharmaceuticals by 6.4% during the fourth quarter. Tanaka Capital Management Inc. now owns 256,593 shares of the biopharmaceutical company’s stock valued at $1,003,000 after buying an additional 15,515 shares during the period. Schwab Charles Investment Management Inc. grew its position in Catalyst Pharmaceuticals by 23.4% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 148,704 shares of the biopharmaceutical company’s stock valued at $582,000 after buying an additional 28,204 shares during the period. Caxton Corp acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at $129,000. Finally, MetLife Investment Advisors LLC acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at $144,000. Institutional investors own 54.66% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate Catalyst Pharmaceuticals (CPRX) Will Announce Earnings of -$0.06 Per Share” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/08/zacks-analysts-anticipate-catalyst-pharmaceuticals-cprx-will-announce-earnings-of-0-06-per-share.html.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.
Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.